1 2	Nykøbing Falster Hospital 28 June 2022
3	IMPACT OF COVID-19 PANDEMIC ON
4	CANCER SCREENING IN DENMARK:
5	A register-based study
6 7 9 10 11 12 13 14 15 16 17 18 19	 Mette Hartmann Nonboe^{1*}, George Napolitano², Jeppe Bennekou Schroll³, Ilse Vejborg⁴, Marianne Waldström⁵, Elsebeth Lynge¹ 1) Centre for Epidemiological Research, Nykøbing Falster Hospital, Nykøbing Falster, Denmark, menon@regionsjaelland.dk, elsebeth@sund.ku.dk 2) Department of Public Health, University of Copenhagen, Copenhagen, Denmark, gena@sund.ku.dk 3) Department of Gynecology and Obstetrics, Copenhagen University Hospital Amager and Hvidovre, Denmark, jeppe.bennekou.schroll.02@regionh.dk
20 21 22 23 24 25 26	 4) Department of Breast Examinations, Copenhagen University Hospital Herlev/Gentofte, Copenhagen, Denmark, <u>ilse.vejborg@regionh.dk</u> 5) Department of Pathology, Aarhus University Hospital, Skejby, Aarhus N, Denmark, <u>mw@profibermail.dk</u>
27 28 29 30 31 32	*Correspondence to: Mette Hartmann Nonboe, Nykøbing Falster Hospital, Ejegodvej 63, DK-4800 Nykøbing Falster, University of Copenhagen, Denmark, Tel: +4528946205 <u>menon@regionsjaelland.dk, ORCID: https://orcid.org/</u> <u>0000-0003-0085-9109</u>

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

33 ABSTRACT

- 34 Background
- 35 Denmark was one of the few countries where it was politically decided to continue cancer
- 36 screening during the COVID-19 pandemic. We assessed the actual population uptake of
- 37 mammography and cervical screening during this period.
- 38 Methods
- 39 The first COVID-19 lockdown in Denmark was announced on 11 March 2020. To investigate
- 40 possible changes in cancer screening activity due to the COVID-19 pandemic, we analysed data
- 41 from the beginning of 2017 until the end of 2021, searching for trends and outliers in the activity
- 42 throughout this period, particularly after the first lockdown. Data on mammography screening and
- 43 cervical screening were retrieved from governmental pandemic-specific monitoring of health care
- 44 activities.
- 45 Results
- 46 A brief drop was seen in screening activity right after the first COVID-19 lockdown, but the activity
- 47 quickly returned to its previous level. A short-term deficit of 43% [-49 to -37] was found for
- 48 mammography screening. A short-term deficit of 62% [-65 to -58] was found for cervical screening.
- 49 Furthermore, a slight, statistically significant downward trend in cervical screening from 2018 to
- 50 2021 was probably unrelated to the pandemic. Other changes, e.g. a marked drop in
- 51 mammography screening towards the end of 2021, also seem unrelated to the pandemic.
- 52 Conclusions
- The policy in Denmark of continuing cancer screening during the pandemic was implemented veryeffectively.
- 55 Funding
- 56 Region Zealand (R22-A597).

57 Introduction

For almost two years, COVID-19 has been a central part of daily life in Denmark. On 11 58 March 2020, when the WHO declared COVID-19 a global pandemic ("WHO Director-59 General's opening remarks at the media briefing on COVID-19 - 11 March 2020"; n.d.), the 60 prime minister of Denmark announced a national lockdown (Danish Government; 2020). 61 In many ways, the first lockdown in Denmark was similar to the handling of the pandemic 62 in other countries with, among other restrictions, temporary suspension of non-urgent 63 health care services. However, as opposed to the situation in e.g. the UK and Italy, the 64 cancer screening programs were not put on hold (Danish Health Authority; 2020a; 65 Morris et al.: 2020: Vanni et al.: 2020). By 22 January 2022, the last COVID-19 66 restrictions in Denmark were repealed. 67

Cancer screening in Denmark is free of charge, so even for citizens economically affected 68 by COVID-19, payment should be no hindrance to participation. However, at the lockdown 69 press conference, the prime minister and the head of the Danish Health Authority focused 70 on the need to protect the health care system by avoiding unnecessary contact with 71 general practitioners (GPs) and Emergency Departments. Some people could have 72 interpreted this as a "stay home" message from cancer screening as well (Wilson et al.; 73 2021). The screening programs could also have been affected by, e.g. relocation of 74 75 personnel to COVID-19 tasks and use of HPV-testing equipment for analysis of COVID-19 tests. For individual citizens existing barriers to participation in cancer screening could also 76 have been enhanced during the pandemic, e.g. difficulties in booking consultations at their 77 GP's (Wilson et al.; 2021), and new barriers could have arisen, such as concern about 78 becoming infected with COVID-19 (Wilson et al.; 2021); concern about unnecessary 79 burdening of the health care system (Wilson et al.; 2021); or simply by changes of 80 priorities (Castanon et al.; 2021). In the present study, we assessed the population's 81 cancer screening uptake during the COVID-19 pandemic in Denmark. 82

83 Material and Methods

84 <u>Setting</u>

Health care in Denmark is financed through taxes, and cancer screening, assessment and
treatment of detected lesions are free of charge for the patient. Denmark has three
national cancer screening programs. First, biennial mammography screening for women

aged 50 to 69 occurs at specialised hospital clinics (Danish Health Authority; 2019a). It 88 is a stand-alone program including only mammography screening taken in the public 89 sector after invitation. In Denmark, opportunistic breast screening is minimal (Jensen et 90 al.; 2005). Second, third or fifth yearly cervical screening for women aged 23 to 64, where 91 samples are collected primarily in the private sector by GPs or office-based gynaecologists 92 (Danish Health Authority: 2020b). It is an integrated program including both cell samples 93 94 collected after invitation, cell samples collected at the woman's/doctor's initiative or collected as a control of a previous abnormal test. A unique screening initiative took place 95 in 2017, where women above 70 had a one-time invitation to screening (*Region* 96 *Midtjylland*; 2018), as this birth cohort has not previously been offered screening. Lastly, 97 biennially screening for bowel cancer of all people aged 50 to 74 with faecal 98 immunochemical test kits sent directly to the person's home (**Danish Health Authority**; 99 **2019b**). The five Danish regions are responsible for the programs, following the Danish 100 Health Authority guidelines. 101

102 Health care activities are registered centrally. Based on these registered data, the Danish Health Authority closely monitored health care activities in hospitals and the private 103 practice sector during the pandemic. From 10 June 2020 and up until 5 January 2022, 104 105 activity data were published regularly in thirteen reports (*Danish Health Authority*; 2021). The present study was based on the activity data collected in this monitoring effort. As only 106 activities in the hospitals and the private sector were monitored, activities in the bowel 107 cancer screening program were not included, as this program is based on self-sampled 108 109 tests.

At mammography screening, two views are taken, a craniocaudal and a mediolateral oblique. The screens are read independently by two radiologists, now in one region by one radiologist and an AI-based system, and if inconsistent, a consensus decision is reached. The screening result is reported as normal or abnormal; in the latter case, the letter is combined with an invitation to clinical assessment. The result is communicated to the woman via her Digital Post for communication with public authorities. For simplicity, we used the term 'mammography screen' for the entire mammography examination.

At cervical screening, a cell-sample is taken by the GP/gynaecologist, placed in a vial, and sent to the regional pathology laboratory for cytology examination, now also primary HPV-

test in an implementation trial. The result is communicated both to the woman and to the
 cell-sample collector. In cases of milder abnormalities, the woman is recommended cell sample control. For more severe abnormalities, the woman is referred to a gynaecologist.

At the start of the lockdown on 13 March 2020, emphasis was, among other things, put on 122 limiting the spread of COVID-19 to health care staff. For the GPs, the Organisation of 123 General Practitioners in Danish called Praktiserende Lægers Organisation, PLO, specified 124 guidelines dividing patient contacts into those needing consultation and those that could 125 be handled by phone/web or could eventually be postponed (DSAM; 2020a). In the first 126 127 GP guideline from 25 March 2020, cervical screening was recommended to be postponed. However, the Danish Health Authority intervened, and nine days later, on 3 April 2020, a 128 new GP guideline stated that cervical screening was not suspended (DSAM; 2020b). 129 Furthermore, to compensate for the observed drop in mammography screening in the 130 131 early phase of the pandemic, all five regions issued extra reminders to women who had cancelled their screening appointments in June and July 2020 (Danish Cancer Society; 132 133 2020a).

Throughout the COVID-19 lockdown, the Danish Cancer Society and news agencies
 regularly reported on the state of cancer-related activities, including trends in numbers of
 mammography screens and cell-samples (*Danish Cancer Society*; 2020b; *Danish Health Authority*; 2021). The Danish Cancer Society encouraged women who had
 skipped cervical screening to book a new appointment with their GP (*Danish Cancer* Society; 2020b).

140 <u>Data</u>

For mammography screening, the government retrieved from the National Patient Register 141 (Landspatientsregistret, LPR) using the activity codes DZ123A (mammography screening), 142 DZ123AA (mammography screening under the Health Act), and DZ108A (now expired 143 code), and the procedure code UXRC45 (mammography, screening) alone or combined 144 with additional diagnosis codes ZPROON (normal test result) and ZPR01N (abnormal test 145 result). The same data source and codes are used in the annual reporting from the Danish 146 Quality Database on Mammography Screening (Danish Quality Database for 147 Mammography Screening. DKMS Report; 2021). Data on cervical screening were 148 retrieved from the Danish Health Insurance Register using the combination of provider 149

- 150 codes 80 (GP) and 07 (office-based gynaecologist) with payment codes 2102 and 4301
- 151 (cervical cell sample). The data source and codes differ from the ones used in the annual
- reporting from the Danish Quality Database on Cervical Cancer Screening (Danish
- 153 Quality Database for Cervical Cancer Screening. DKLS Report 2021; 2022) where
- data are retrieved from the National Pathology Register. We retrieved data from 2017 to
- 155 2021, with the period before 13 March 2020 representing the pre-COVID-19 period.
- All data were available in weekly aggregated form, using a standard ISO-week numbering
- 157 system. The Danish Health Data Authority provided mammography data for 2017-2021.
- 158 Cell sample data for 2017-2019 and from weeks 34-52 in 2021 were provided by the
- 159 Danish Health Data Authority, while we extracted cell-sample data from 2020 and weeks
- 160 1-33 in 2021 from eSundhed.dk (*Danish Health Data Authority*; n.d.).

Mammography screening							Cervical screening				
Region	Year 2017	Year 2018	Year 2019	Year 2020	Year 2021	Year 2017	Year 2018	Year 2019	Year 2020	Year 202	
Denmark	289,150	290,275	282,426	260,508	270,303	442,955	348,802	342,408	306,358	325,920	
Capital	78,323	75,415	75,964	65,012	51,457	155,024	124,118	119,821	110,625	117,256	
Central	67,282	68,117	66,895	63,043	69,719	97,668	77,141	83,618	71,938	76,798	
North	30,835	31,033	30,415	31,978	26,532	43,780	34,431	33,453	29,285	33,751	
South	42,314	46,242	40,881	64,108	72,876	88,513	67,882	64,816	57,112	59,140	
Zealand	70,396	69,468	68,271	36,367	49,719	57,970	45,230	40,700	37,398	38,975	

Table 1. Number of mammography and cervical screens by year and region, Denmark 2017-2021

163 Source: Own calculations based on numbers provided by the Danish Health Data Authority

164 Data analysis

- To identify a possible impact of the COVID-19 epidemic on cancer screening activity, we undertook a time series analysis. To easily identify seasonal patterns, especially moving holidays, e.g. Easter, summer holidays, etc., data were split into periods of 4 weeks, called "months" in the rest of this paper, making a total of 13 months per year, with week 53 of 2020, a leap year, included in month 13 (*appendix table 1*).
- 170 Seasonal and trend patterns were then identified through a Seasonal Decomposition of
- 171 Time Series by Loess (STL decomposition) with robust fitting. The seasonal-adjusted time
- series, i.e. the original time series without the seasonal component, were then modelled
- 173 with a negative binomial integer-valued GARCH model with a logarithmic link (*Liboschik*
- 174 *et al.*; 2017). Outliers and linear trends in the time series were identified through graphical
- inspection and analytical procedure. In particular, outliers were identified through the
- procedures described in Liboschik et al.; here, outliners are named "interventions"
- 177 (*Liboschik et al.*; 2017) and in (*López-de-Lacalle*; 2019) using the "tso function" in the
- tsoutlier package. Linear trends were found by searching for a statistically significant linear
- term in the regression model. Once a liner trend was identified, the start date was chosenas the date minimizing the AIC of the model.
- All analyses and plots were done using R ver. 4.1.1 (*R Core Team*; 2021), with the
- package collection tidyverse (*Wickham et al.*; 2019) and the packages tscount (*Liboschik*
- 183 et al.; 2017) and tsoutlier (*López-de-Lacalle*; 2019)
- 184 <u>Ethics</u>


According to Danish legislation, ethical approval was not needed for this study as it is

- 186 entirely based on aggregated, publicly available register data.
- 187 **Results**
- 188 <u>Mammography screening</u>
- 189 On average, 287,284 mammography screenings were performed annually from 2017 to
- 190 2019, compared with 260,508 in 2020 and 270,303 in 2021 (*Table 1*).
- 191 The time trend analysis for mammography screening is illustrated in Figures 1-4. Figure 1
- depicts the observed weekly number of mammography screening. Figure 2 shows the

decomposition of the monthly data. In the seasonal component, one can clearly identify
the prominent low peaks due to Easter, month 4, summer, month 8, and Christmas, month
13. Figure 3 illustrates the seasonal-adjusted monthly data. In Figure 4, the fitted model is
depicted together with the seasonal-adjusted data.

We found that from 24 February 2020 to 22 March 2020, there was a -22.6% [CI -30.1 to 197 -14.4] reduction in the number of mammography screenings, and from 23 March 2020 to 198 19 April 2020, a -43.3% [CI -49.0 to -36.9] reduction (Figure 4 and Table 2). The activity 199 200 decline was short-termed; however, it did not reach the previous levels in the first months after the first lockdown. Pre-lockdown levels were reached only after the issue of additional 201 extra reminders for examination. There was a statistically significant decrease of -17.0% 202 [CI -21.2 to -12.6] in the number of mammography screens from 16 August 2021 to 2 203 January 2022 (Figure 4). All percentages were with respect to the expected number in the 204 205 absence of the outlier. Separating the numbers by region, the Capital Region and the much smaller Region North were responsible for the drop at the end of 2021 206 207 (supplementary material S1-2). In the Capital Region, from 19 June 2021 to 15 August 2021, the decrease was -34.0% [CI -43.4 to -23.1]; from 16 August 2021 to 12 September 208 209 2021 -67.2% [CI -72.1 to -61.3]; from 13 September 2021 to 10 October 2021 -85.3% [CI -88.1 to -81.9], and from 11 October 2021 to 2 January 2022 -41.3% [CI -49.5 to -31.8]. 210






212


213 Source: Own calculations based on numbers provided by The Danish Health Data Authority

Figure 2. Decomposition of time series in number of mammography screens into seasonal, trend, 214 and irregularcomponent, Denmark 2017-2021. 215



229 Source: Own calculations based on numbers provided by The Danish Health Data Authority


Figure 3. Seasonal-adjusted time series of the number of mammography screens, Denmark 2017-2021.



233 Source: Own calculations based on numbers provided by The Danish Health Data Authority

232

Figure 4. Seasonal-adjusted time series and fitted model of the number of mammography screens,
 Denmark 2017-2021.



236

237 Source: Own calculations based on numbers provided by The Danish Health Data Authority

Table 2. Estimated changes in number of seasonally adjusted mammography screens. Denmark 238 239 and regions, 2017-2021. Reductions and increases are with respect to the average base line.


	Time period	Estimated change in percent
Denmark	24 February 2020 – 22 March 2020 23 March – 19 April 2020 16 August 2021 – 02 January 2022	-22.6% [CI -30.1 to -14.4] -43.3% [CI -49.0 to -36.9] -17.0% [CI -21.2 to -12.6]
Capital	30 December 2019 – 18 July 2021 23 March 2020 – 19 April 2020 19 July 2021 – 15 August 2021 16 August 2021 – 12 September 2021 13 September 2021 – 10 October 2021 11 November 2021 – 02 January 2022	-11.8% [Cl -15.7 to -7.7] - (level shift) -43.5% [Cl -51.6 to -34.1] -34.0% [Cl -43.4 to -23.1] -67.2 [Cl -72.1 to -61.3] -85.3 [Cl -88.1 to -81.9] -41.3 [Cl -49.5 to -31.8]
entral	24 February 2020 – 22 March 2020 23 March 2020 – 19 April 2020	-15.7% [Cl -24.4 to -6.1] -38.2% [Cl -44.7 to -30.9]
North	24 May 2021 – 02 January 2022	7.5% [CI 5.1 to 9.9]
South	23 March 2020 – 19 April 2020	-43.5% [CI -53.5 to -31.4]
Zealand	24 February 2020 – 19 April 2020 02 November 2020 – 02 January 2022	-51.5% [Cl -58.5 to -43.3] 1.6% [Cl 0.7 – 2.5]


240

241 Source: Own calculations based on numbers provided by The Danish Health Data Authority

242 <u>Cervical screening</u>

- On average, 345,605 cell samples were collected annually from 2018 to 2019, compared with 306,358 in 2020 and 325,920 in 2021 (*Table 1*).
- The time series analysis for cervical screening is illustrated in Figures 5-6. Analysis was
- done the same way for mammography screening analysis (figures not shown). Overall,
- there was an annual, statistically significant reduction of -1.9% [CI -2.9 to -0.8] from 6
- November 2017 to 2 January 2022 in the number of cell-samples in Denmark (*Table 3*).
- 249 There was a drop in activity of -30.7% [CI -36.5 to -24.3] from 24 February 2020 to 22
- 250 March 2020, and of -61.9% [CI -65.2 to -58.2] from 23 March 2020 to 19 April 2020 (*Table*
- 3). Hereafter, activity returned to the previously (linearly decreasing) level. Unexpectedly,
- there was a drop in activity from 21 June 2021 to 18 July 2021 of -20.3% [CI -27.1 to -12.9]
- 253 (*Figure 6, Table 3*).
- 254 When the data from Denmark were split by region, the numbers from Capital Region,
- Region Zealand and Region Central followed the national trend (*S2, Table 3*). Region
- North had an annual reduction of -6.9% [CI -8.9 to -4.8] from 9 September 2019 to 2
- 257 January 2022, and Region South of -5.0% [CI -6.4 to -3.6] from 1 January 2018 to 2
- January 2022 (S2, Table 3). The drop around 1 July 2021 was seen in all regions except
- 259 Region North.





261





Figure 6. Seasonal-adjusted monthly time series and fitted model of the number of cervical cancer 263 screens, Denmark 2017-2021. 264



278 Source: Own calculations based on numbers provided by The Danish Health Data Authority.

- Table 3. Estimated changes in number of seasonally adjusted cervical cell-samples. Denmark and 279
- regions, 2018-2020. Reductions and increases are with respect to the average base line. 280

	Time period	Estimated change in percent
Denmark	6 November 2017 – 02 January 2022 24 February 2020 – 22 March 2020 23 March – 19 April 2020 21 June 2021 – 18 July 2021	-1,9% [Cl -2.9 to -0.8] annual reduction -30.7% [Cl -36.5 to -24.3] -61.9% [Cl -65.2 to -58.2] -20.3% [Cl -27.1 to -12.9]
Capital	24 February 2020 – 22 March 2020 23 March 2020 – 19 April 2020 21 June 2021 – 18 July 2021	-32.4% [CI -38.1 to -26.1] -57.9% [CI -61.7 to -53.7] -23.8% [CI -30.3 to -16.8]
Central	24 February 2020 – 22 March 2020 23 March 2020 – 19 April 2020 21 June 2021 – 18 July 2021	-31.0% [CI -37.6 to -23.8] -62.8% [CI -66.6 to -58.5] -24.0 [CI -31.2 to -16.0]
North	09 September 2019 – 02 January 2022 24 February 2020 – 22 March 2020 23 March 2020 – 19 April 2020 29 March 2021 –25 April 2021	-6.9% [CI -8.9 to -4.8] annual reduction -33.9% [CI -41.5 to -25.3] -61.1% [CI -65.9 to -55.5] 94.% [CI 72.9 to 118.89]
South	01 January 2018 – 02 January 2022 23 March 2020 – 19 April 2020 21 June 2021 – 18 July 2021	- 5.0% [CI -6.4 to -3.6] annual reduction -60.4% [CI -64.4 to -55.9] -19.6 [CI -27.6 to -10.8]
Zealand	23 March 2020 – 19 April 2020 01 March 2021 – 28 March 2021 21 June 2021 – 18 July 2021	-67.6% [CI -71.8 to 62.7] 31.9% [CI 16.0 to 50.0] -12.7% [CI -23.4 to 0.6]

281

Source: Own calculations based on numbers provided by The Danish Health Data Authority.

282 Discussion

283 Main finding

A survey undertaken by the International Cancer Screening Network documented that Denmark was one of the few countries where the health authorities did not suspend cancer screening during the COVID-19 pandemic (*Puricelli Perin et al.*; *2021*). Here we demonstrated that this policy was largely followed, as only a brief drop was seen in the screening activity following the lockdown of the society on 13 March 2020.

Our analysis also illustrated the difficulties of using time series analysis in assessing a

causal association between the COVID-19 pandemic and screening activity, as activity

291 patterns were also affected by other societal circumstances, such as the shortage of

radiologists.

For cervical screening, except during the unique initiative for screening of elderly women in 293 2017, our data indicated a slight, statistically significant downward trend in cervical 294 295 screening activity. A more detailed analysis showed that this was limited to two of the five Danish regions. We do not know the reason for this phenomenon. Furthermore, in mid-296 297 2021, there was a temporal drop in activities in four out of five regions. It coincided with a national nurse strike, which is unlikely to be directly linked to the drop, as the strike did not 298 involve nurses employed in GP/gynaecologist practices. It could have affected the minor 299 300 part of the screening activity that the hospitals undertake.

For mammography screening, our data showed a steep decrease in the screening activity 301 during the second half of 2021, limited to two of the five Danish regions. In Denmark, the 302 same staff works in screening and diagnostic mammography, and the Capital Region 303 decided to limit the number of screening invitations in August-October 2021 to 25% of the 304 normal level to meet the time limits for diagnostic mammography set in the Danish breast 305 cancer patient package. Incidentally, this was well captured by our model. During this 306 307 period, the mammography service in the Capital Region underwent organisational 308 changes, moved location, acquired new equipment, and implemented an AI reader.

309 Strength and limitations

The main strength of this study was the usage of nationwide register data.

In Denmark, all health care activities are registered in national databases. During the 311 COVID-19 pandemic, the Danish Health Authority used the Danish Health Insurance 312 Register to monitor cervical screening. In Denmark, GPs and office-based gynaecologists 313 are fee-for-service paid by the government, and these payments are registered in the 314 Danish Health Insurance Register. Therefore, the completeness of the data depends on 315 the screening providers' use of correct payment codes and timely reporting. In the annual 316 monitoring of cervical screening, undertaken by the regions and reported in DKLS, data 317 are retrieved from the National Pathology Register, which covers all pathology specimens 318 analysed in Denmark. Nationwide, there was a difference between the two datasets in 319 2021, with 323,598 cell-samples in our dataset and 372,508 in DKLS, Table 4. As the 320 DKLS data are expected to be complete, 13% of cell-samples from 2021 were thus 321 missing in our data, but the time trends are expected to be the same. 322

323 The Danish Health Authority used the National Patient Register as a source for the COVID-19 monitoring reports. DKMS use the same data source. As our data are reported 324 325 by year, and DMKS' data are reported by screening invitation-round, the numbers are not directly comparable. However, when corrected for length of period, we had 5% more 326 screens than DKMS, Table 4. The deficit in DKMS data derived almost entirely from two of 327 328 the five Danish regions, which might partly be due to different dates for data retrieval. A further limitation was that we used the number of tests to analyse trends, not considering 329 that the size of the screening target groups could vary slightly over the years. It should 330

also be noted that it is impossible to make a causal conclusion based on a trend analysis.

Another limitation was that we reported on tests performed and not on women examined.

Table 4. Comparing data from present study with data from the Danish Quality Database for Mammography Screening, 6th screening

round (Danish Quality Database for Mammography Screening. DKMS Report; 2021) and data from the Danish Quality Database for

335 Cervical Cancer Screening (*Danish Quality Database for Cervical Cancer Screening. DKLS Report 2021; 2022*)

Region									
	6 th screening round	DKMS	Present study	Difference	Difference (%)	DKLS (2021)	Present study	Difference	Difference (%)
Denmark		577,753	605,575	27,822	4.82	372,508	323,598	48,910	-13.13
Capital	01-07-2018 to 01-10-2020	159,751	161,650	1899	1.19	130,499	116,145	14,354	-11
Central	01-01-2018 to 31-12-2019	133,305	135,282	1977	1.48	87,520	75,967	11,553	-13.2
North	01-02-2018 to 17-03-2020	63,368	63,522	154	0.24	35,468	32,288	3,180	-8.97
South	01-08-2018 to 31-08-2020	129,879	140,591	10,712	8.25	72,850	59,738	13,112	-18
Zealand	01-08-2018 to 19-02-2021	91,450	104,531	13,081	14.3	46,171	39,460	6,711	-14.54
36	0.0010.0010.0101011001	01,100		.0,001				6,7.1.	

337 Source: Own calculations based on numbers provided by the Danish Health Data Authority and data from the Danish Quality Database on Breast

338 Cancer Screening

339 The Breast cancer screening rounds run for very different periods in each region. Therefore, the dates for the sixth round are listed. All cervical cancer

340 screening data are reported on yearly basis, from 1 January to 31 December.

341 Other studies

- During the first three months of the COVID-19 pandemic in Denmark, the number of 342 cancer diagnoses dropped by one-third compared with previous years (Skovlund et al., 343 **2020**). Early during the lockdown, the Danish Cancer Society collected information from 344 screening providers and reported decreased participation in mammography and cervical 345 screening (Danish Cancer Society; 2020a, 2020b). According to the DKLS 2020 report, 346 there was a drop in cervical screens by approximately 10% from 2019 to 2020 is 347 suggested to be related to COVID-19 and the lockdown (Waldstrøm et al.; 2021). 348 349 In the Netherlands, suspension of the breast cancer screening programme was associated with a substantial decrease in women diagnosed with breast cancer in the first weeks after 350 suspension, and the number remained low until June 2020 (Dinmohamed et al.; 2020). 351
- Australia experienced decreased capacity after resuming the breast screening program,
- Australia experienced decreased capacity after resuming the breast screening program only reaching 83% of the 2018-level (*Feletto et al.*; *2020*). This could eventually delay
- 354 screening and result in disease progression (*Davies et al.*; 2022; *Wilson et al.*; 2021).
- In the UK, Wilson et al. undertook a mixed-method study in August-November 2020, 355 comprising an online survey and qualitative interviews. In the survey, 30% answered that 356 they were less likely to attend cervical screening than before the corona pandemic 357 lockdown, and 75% declared that they were worried about delay in cancer screening 358 caused by COVID-19 (*Wilson et al.*: 2021). Although reluctance to participate in cervical 359 screening is not a new phenomenon, especially among young women and college 360 graduates (Wenger et al.; 2022), further cancellation related to the pandemic could 361 362 potentially have long-term consequences, as participation in screening once is a predictor of participation in the future (Kotzur et al.; 2020; Wilson et al.; 2021). The pandemic 363 could therefore in particular be expected to affect women scheduled to enter the screening 364 program during the pandemic (*Wilson et al.*; 2021). Moreover, vulnerable groups who 365 have been advised to be careful during the pandemic would weigh the pros and cons of 366 screening against the risk of COVID-19 infection (*Walker et al.*; 2021). 367

368 Public health implications

Besides a steep, temporal drop in screening activity following the WHO declaration of the pandemic and the simultaneous lockdown of the Danish society, COVID-19 did not affect

cancer screening in Denmark. The focused policy of keeping screening going was a
decisive factor. Political decisions were communicated from the Danish Health Authority to
the five regions responsible for cancer screening. The Danish Cancer Society and the
press also played an essential role in repeatedly reporting cancer screening status. The
initial suspension in marts 2020 of cervical screening undertaken by GPs was revoked
within nine days, and extra reminders for mammography screening were issued when realtime monitoring data indicated a decrease in activity.

- The very possibility of continuing screening during the pandemic was undoubtedly
- facilitated by the robustness of the health care system. During the period, March 2020-
- December 2021, 3550 persons in Denmark died with COVID-19 (*Neergaard*; 2022),
- constituting 3.6% out of a total number of 99,000 deaths in the period ("Statistikbanken;"
- **n.d.**). Life expectancy increased from 2018/2019 to 2019/2020 for both men and women
- but levelled off from 2019/2020 to 2020/21; for men changing from 79.5 to 79.6 years, and
- for women slightly decreased from 83.6 to 83.4 years ("Statistikbanken;" n.d.). The
- 385 COVID-19 lockdown period was nevertheless a period where health care resources were
- 386 stretched far beyond the normal level. After a breakdown of negotiations on a new
 - agreement, the nurses went on strike in June-July 2021, causing further delays in elective
- treatment, e.g. hip-replacement (*TV2 News*; *2021*).
- As handling cancer screening during an extraordinary situation like the COVID-19
- 390 pandemic depends on the local organisation and resources, the experiences from
- 391 Denmark can probably not be generalised to all settings. Nevertheless, the example
- illustrated the potentials for health policy implementation in a high-income, welfare state
- 393 with a publicly run health care system

394 Conclusion

In Denmark, it was decided politically to continue mammography and cervical screening throughout the COVID-19 pandemic in 2020 and 2021. Our study showed that screening activity dropped at the time of the first lockdown of the society but very rapidly went back to the pre-pandemic level.

399 Acknowledgements

- 400 The Danish Health Data Authority provided data for the study. Region Zealand financially
- supported the study (grant number: R22-A597). The funder had no impact on the study
- design and interpretation of data.

403 **Competing interests**

- 404 Elsebeth Lynge received HPV-test kits from Roche for a method study. The remaining
- authors have no conflicts of interest to declare.

Reference: 406

407	Castanon A, Rebolj M, Burger EA, de Kok IMCM, Smith MA, Hanley SJB, Carozzi FM, Peacock S, O'Mahony
408	JF. 2021. Cervical screening during the COVID-19 pandemic: optimising recovery strategies. Lancet
409	<i>Public Health</i> 6 :e522–e527. doi:10.1016/S2468-2667(21)00078-5
410	Danish Cancer Society. 2020a. Aflyste du din screening for brystkræft under coronakrisen? Sig ja tak til at få
411	en ny tid! <i>Kræft Bekæmp</i> . https://www.cancer.dk/nyheder/aflyste-du-din-screening-for-
412	brystkraeft-under-coronakrisen-sig-ja-tak-til-at-faa-en-ny-tid/
413	Danish Cancer Society. 2020b. Husk at bestille tid til den celleprøve, du aflyste under coronakrisen. Kræft
414	Bekæmp. https://www.cancer.dk/nyheder/husk-at-bestille-tid-til-den-celleproeve-du-aflyste-
415	under-coronakrisen/
416	Danish Government. 2020. The Prime Minister: We will need to help each other. Pressmeeting on
417	Coronavirus. https://www.regeringen.dk/nyheder/2020/pressemoede-11-marts-i-spejlsalen/
418	Danish Health Authority. 2021. COVID-19: Monitoring of activity i the health care system in Denmark.
419	Danish Health Authority. 2020a. Handling of COVID-19: Description of critical functions in the health care
420	system under COVID-19.
421	Danish Health Authority. 2020b. Cervical cancer screening.
422	https://www.sst.dk/da/Udgivelser/2018/Screening-for-livmoderhalskraeft
423	Danish Health Authority. 2019a. Breast cancer screening.
424	https://www.sst.dk/da/viden/screening/screening-for-kraeft/brystkraeft
425	Danish Health Authority. 2019b. Bowel cancer screening.
426	https://www.sst.dk/da/Viden/Screening/Screening-for-kraeft/Tarmkraeft
427	Danish Health Data Authority. n.d. Monitoring of the reopening of the healt care system.
428	https://www.esundhed.dk/Emner/Patienter-og-sygehuse/Monitorering-af-genaabningen-af-
429	sundhedsvaesnet
430	Danish Quality Database for Cervical Cancer Screening. DKLS Report 2021. 2022 .
431	Danish Quality Database for Mammography Screening. DKMS Report. 2021 .
432 433	Davies JM, Spencer Al, Macdonald S, Dobson L, Haydock E, Burton H, Angelopoulos G, Martin-Hirsch P, Wood NJ, Thangavelu A, Hutson R, Munot S, Flynn M, Smith M, Decruze B, Myriokefalitaki E, Sap
435 434	K, Winter-Roach B, Macdonald R, Edmondson RJ. 2022. Cervical cancer and COVID: an assessment
435	of the initial effect of the pandemic and subsequent projection of impact for women in England: A
436	cohort study. <i>BJOG Int J Obstet Gynaecol</i> . doi:10.1111/1471-0528.17098
437	Dinmohamed AG, Cellamare M, Visser O, de Munck L, Elferink MAG, Westenend PJ, Wesseling J, Broeders
438	<i>MJM, Kuipers EJ, Merkx MAW, Nagtegaal ID, Siesling S. 2020</i> . The impact of the temporary
439	suspension of national cancer screening programmes due to the COVID-19 epidemic on the
440	diagnosis of breast and colorectal cancer in the Netherlands. J Hematol Oncol J Hematol Oncol
441	13 :147. doi:10.1186/s13045-020-00984-1
442	DSAM . 2020a . Suggestion to limit the spread of disease in private practices - Yellow-Green list.
443	DSAM . 2020b. News on Coronavirus - DSAM - Danish Society for Flere nyheder vedr. coronavirus - DSAM -
444	The Danish College of General Practitioners (Dansk Selskab for Almen Medicin).
445	https://www.dsam.dk/forsiden/coronavirus/flere_nyheder_vedr_coronavirus/
446	Feletto E, Grogan P, Nickson C, Smith M, Canfell K. 2020. How has COVID-19 impacted cancer screening?
447	Adaptation of services and the future outlook in Australia. Public Health Res Pract 30:3042026-
448	3042026. doi:10.17061/phrp3042026
449	Jensen A, Olsen AH, von Euler-Chelpin M, Helle Njor S, Vejborg I, Lynge E. 2005. Do nonattenders in
450	mammography screening programmes seek mammography elsewhere? Int J Cancer 113 :464–470.
451	doi:10.1002/ijc.20604
452	Kotzur M, McCowan C, Macdonald S, Wyke S, Gatting L, Campbell C, Weller D, Crighton E, Steele RJC,
453	Robb KA. 2020. Why colorectal screening fails to achieve the uptake rates of breast and cervical

454 455	cancer screening: a comparative qualitative study. <i>BMJ Qual Saf</i> 29 :482–490. doi:10.1136/bmjqs- 2019-009998
456	Liboschik T, Fokianos K, Fried R. 2017. tscount : An R Package for Analysis of Count Time Series Following
457	Generalized Linear Models. J Stat Softw 82:1–51. doi:10.18637/jss.v082.i05
458	<i>López-de-Lacalle J.</i> 2019. tsoutliers: Detection of Outliers in Time Series. https://CRAN.R-
459	project.org/package=tsoutliers
460	Morris M, Nolte E, Aggarwal A, Spicer J, Purushotham A, Sullivan R, Aggarwal Ajay, Maringe C, Spicer
461	James, Morris Melanie, Purushotham Arnie, Nolte Ellen, Sullivan Richard, Rachet B. 2020. The
462	impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a
463	national, population-based, modelling study. Artic Lancet Oncol 21 :1023–1057. doi:10.1016/S1470-
464	2045(20)30388-0
465	Neergaard ASF . 2022 . Danmarks Statistik: COVID-19: Næsten dobbelt så høj dødelighed for mænd.
466	https://www.dst.dk/da/Statistik/nyheder-analyser-publ/bagtal/2022/2022-05-04-doede-med-covid
467	Puricelli Perin DM, Elfström KM, Bulliard J-L, Burón A, Campbell C, Flugelman AA, Giordano L, Kamineni A,
468	Ponti A, Rabeneck L, Saraiya M, Smith RA, Broeders MJM. 2021. Early assessment of the first wave
469	of the COVID-19 pandemic on cancer screening services: The International Cancer Screening
470	Network COVID-19 survey. <i>Prev Med</i> 151 :106642. doi:10.1016/j.ypmed.2021.106642
471	R Core Team . 2021 . R: A language and environment for statistical computing. R Foundation for Statistical
472	Computing.
473	Region Midtjylland. 2018. ScreeningsNyt. ScreeningsNyt - Januar 2018.
474	Skovlund CW, Friis S, Dehlendorff C, Nilbert C, Mørch LS. n.d. Hidden morbidities: drop in cancer diagnoses
475	during the COVID-19 pandemic in Denmark. doi:10.1080/0284186X.2020.1858235
476	Statistikbanken. n.d. https://www.statistikbanken.dk/20014
477	Statistikbanken. n.d. https://www.statistikbanken.dk/20015
478	TV2 News . 2021 . Flere tusinder har fået udskudt deres operation: - Jeg venter på at blive undersøgt for
479	cancer - TV 2. <i>nyheder.tv2.dk</i> . https://nyheder.tv2.dk/samfund/2021-08-11-flere-tusinder-har-
480	faaet-udskudt-deres-operation-jeg-venter-paa-at-blive
481	Vanni G, Pellicciaro M, Materazzo M, Bruno V, Oldani C, Pistolese CA, Buanomo C, Caspi J, Gualtieri P,
482	Chiaravalloti A, Palambi L, Piccione E, Buonomo OC. 2020. Lockdown of Breast Cancer Screening
483	for COVID-19: Possible Scenario. <i>In Vivo</i> 34 :3047–3047. doi:10.21873/INVIVO.12139
484	Waldstrøm M, Reza Serizawa, Berit Andersen, Anne Poulsgaard Frandsen, Rouzbeh Salmani, Susanne
485	Nielsen, Kirsten Jochumsen, Mary Holten Bennetsen, Hanne Nørgaard Heje, Dorthe Ørnskov,
486	Maja Ulrikka Bruun Laustsen, Elsebeth Lynge, Petra Birgitta Hall, Ane Birgitte Telén Andersen,
487	Else Helene Ibfelt. 2021. Dansk kvalitetsdatabase for livmoderhalskræftscreenning - resumé af
488	årsrapport 2020. Ugeskr Læg.
489	Walker MJ, Meggetto O, Gao J, Espino-Hernández G, Jembere N, Bravo CA, Rey M, Aslam U, Sheppard AJ,
490	Lofters AK, Tammemägi MC, Tinmouth J, Kupets R, Chiarelli AM, Rabeneck L. 2021. Measuring the
491	impact of the COVID-19 pandemic on organized cancer screening and diagnostic follow-up care in
492	Ontario, Canada: A provincial, population-based study. Prev Med 151:106586.
493	doi:10.1016/j.ypmed.2021.106586
494	Wenger NS, Stanton AL, Baxter-King R, Sepucha K, Vavreck L, Naeim A. 2022. The Impact of COVID-19 on
495	Routine Medical Care and Cancer Screening. J Gen Intern Med. doi:10.1007/s11606-021-07254-x
496	WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020. n.d.
497	https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-
498	at-the-media-briefing-on-covid-1911-march-2020
499	Wickham H, Averick M, Bryan J, Chang W, McGowan L, François R, Grolemund G, Hayes A, Henry L,
500	Hester J, Kuhn M, Pedersen T, Miller E, Bache S, Müller K, Ooms J, Robinson D, Seidel D, Spinu V,
501	Takahashi K, Vaughan D, Wilke C, Woo K, Yutani H. 2019. Welcome to the Tidyverse. J Open
502	Source Softw 4 :1686. doi:10.21105/joss.01686

- 503 Wilson R, Quinn-Scoggins H, Moriarty Y, Hughes J, Goddard M, Cannings-John R, Whitelock V, Whitaker 504 KL, Grozeva D, Townson J, Osborne K, Smits S, Robling M, Hepburn J, Moore G, Gjini A, Brain K,
- 505 Waller J. 2021. Intentions to participate in cervical and colorectal cancer screening during the
- COVID-19 pandemic: A mixed-methods study. Prev Med 153:106826. 506
- 507 doi:10.1016/j.ypmed.2021.106826

508 Appendix


Table 1. Overview of dates within "Months"

	2017		2018		2019		2020		2021	
Month	Start date	End date								
01	2017-01-02	2017-01-29	2018-01-01	2018-01-28	2018-12-31	2019-01-27	2019-12-30	2020-01-26	2021-01-04	2021-01-31
02	2017-01-30	2017-02-26	2018-01-29	2018-02-25	2019-01-28	2019-02-24	2020-01-27	2020-02-23	2021-02-01	2021-02-28
03	2017-02-27	2017-03-26	2018-02-26	2018-03-25	2019-02-25	2019-03-24	2020-02-24	2020-03-22	2021-03-01	2021-03-28
04	2017-03-27	2017-04-23	2018-03-26	2018-04-22	2019-03-25	2019-04-21	2020-03-23	2020-04-19	2021-03-29	2021-04-25
05	2017-04-24	2017-05-21	2018-04-23	2018-05-20	2019-04-22	2019-05-19	2020-04-20	2020-05-17	2021-04-26	2021-05-23
06	2017-05-22	2017-06-18	2018-05-21	2018-06-17	2019-05-20	2019-06-16	2020-05-18	2020-06-14	2021-05-24	2021-06-20
07	2017-06-19	2017-07-16	2018-06-18	2018-07-15	2019-06-17	2019-07-14	2020-06-15	2020-07-12	2021-06-21	2021-07-18
08	2017-07-17	2017-08-13	2018-07-16	2018-08-12	2019-07-15	2019-08-11	2020-07-13	2020-08-09	2021-07-19	2021-08-15
09	2017-08-14	2017-09-10	2018-08-13	2018-09-09	2019-08-12	2019-09-08	2020-08-10	2020-09-06	2021-08-16	2021-09-12
10	2017-09-11	2017-10-08	2018-09-10	2018-10-07	2019-09-09	2019-10-06	2020-09-07	2020-10-04	2021-09-13	2021-10-10
11	2017-10-09	2017-11-05	2018-10-08	2018-11-04	2019-10-07	2019-11-03	2020-10-05	2020-11-01	2021-10-11	2021-11-07
12	2017-11-06	2017-12-03	2018-11-05	2018-12-02	2019-11-04	2019-12-01	2020-11-02	2020-11-29	2021-11-08	2021-12-05
13	2017-12-04	2017-12-31	2018-12-03	2018-12-30	2019-12-02	2019-12-29	2020-11-30	2021-01-03	2021-12-06	2022-01-02

511 512	Nykøbing Falster Hospital	25 June 2022
513	IMPACT OF COVID-19 PANDEMIC ON	
514	CANCER SCREENING IN DENMARK:	
515	A register-based study	
516 517 518	Mette Hartmann Nonboe ^{1*} , George Napolitano ² , Jeppe Bennekou Schroll ³ , J Marianne Waldström ⁵ , Elsebeth Lynge ¹	lse Vejborg ⁴ and

519 Supplementary material


- 520 **S1**. Seasonal-adjusted time series and fitted model of the number of mammography screens, by 521 region 2017-2021
- 522



523 Source: Own calculations based on numbers provided by The Danish Health Data Authority.

524 Because of high variations in number of performed mammographies between the regions in Denmark, the y-525 axes are different.

526 **S2.** Seasonal-adjusted time series and fitted model of the number of cervical cancer screens, by 527 region 2017-2021



554 Because of high variations in number of performed cervical screens between the regions in Denmark, the y-

⁵⁵⁵ axes are different